Can you develop a drug for a disease that no longer exists? That’s what scientists at SIGA Technologies wondered two decades ago, when they set out to make a smallpox therapy in case the eradicated virus was ever used as a bioweapon. U.S. regulators approved the resulting oral antiviral, TPOXX (tecovirimat), largely based on animal data. Now it has become a crucial treatment for people infected with the monkeypox virus, a smallpox relative that caused a significant outbreak this year. The European Medicines Agency authorized its use for that virus in January; the FDA approved a new intravenous formulation in May. But prescribing TPOXX remains a byzantine process in the U.S., since the drug is only experimentally allowed for use against monkeypox; SIGA’s Chief Scientific Officer Dennis Hruby says the company is working toward full licensure.
- The 100 Most Influential People of 2024
- Coco Gauff Is Playing for Herself Now
- Scenes From Pro-Palestinian Encampments Across U.S. Universities
- 6 Compliments That Land Every Time
- If You're Dating Right Now, You're Brave: Column
- The AI That Could Heal a Divided Internet
- Fallout Is a Brilliant Model for the Future of Video Game Adaptations
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time
